Marvin Caruthers - Viridian Therapeutics CoFounder Member

0K1R Stock   21.75  0.38  1.72%   

Founder

Marvin Caruthers is CoFounder Member of Viridian Therapeutics
Age 84
Address 221 Crescent Street, Waltham, MA, United States, 02453
Phone617 272 4600
Webhttps://www.viridiantherapeutics.com

Viridian Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.3215) % which means that it has lost $0.3215 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5188) %, meaning that it generated substantial loss on money invested by shareholders. Viridian Therapeutics' management efficiency ratios could be used to measure how well Viridian Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Viridian Therapeutics' Total Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 1 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 2.5 M in 2024.

Similar Executives

Found 2 records

FOUNDER Age

Thomas FristHCA Healthcare
85
MD FristHCA Healthcare
85
Viridian Therapeutics (0K1R) is traded on London Exchange in UK and employs 94 people. Viridian Therapeutics is listed under Environmental & Facilities Services category by Fama And French industry classification.

Management Performance

Viridian Therapeutics Leadership Team

Elected by the shareholders, the Viridian Therapeutics' board of directors comprises two types of representatives: Viridian Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viridian. The board's role is to monitor Viridian Therapeutics' management team and ensure that shareholders' interests are well served. Viridian Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viridian Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
MD MBA, Chief Officer
Seth Harmon, Principal Accounting
Anthony Casicano, Chief Officer
Melissa Manno, Chief Officer
John Jordan, Vice Communications
Marvin Caruthers, CoFounder Member
Anthony Casciano, Chief Officer
MBA JD, President CEO
Jennifer JD, Chief Officer
Eric Olson, CoFounder Board
Vahe Bedian, CoFounder Advisor

Viridian Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Viridian Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Viridian Stock Analysis

When running Viridian Therapeutics' price analysis, check to measure Viridian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viridian Therapeutics is operating at the current time. Most of Viridian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viridian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viridian Therapeutics' price. Additionally, you may evaluate how the addition of Viridian Therapeutics to your portfolios can decrease your overall portfolio volatility.